Advanced search
Publication Cover
Cancer Biology & Therapy Volume 19, 2018 - Issue 5
Submit an article Journal homepage
1,259
Views
1
CrossRef citations to date
0
Altmetric
Bedside to Bench Report

Capture-based ultra-deep sequencing in plasma ctDNA reveals the resistance mechanism of ALK inhibitors in a patient with advanced ALK-positive NSCLC

Jing GuoDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, ChinaView further author information
,
Lihong GuoDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, ChinaView further author information
,
Li SunDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, ChinaView further author information
,
Zhenzhen WuDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, ChinaView further author information
,
Junyi YeBurning Rock Biotech, Guangzhou, Guangdong Province, ChinaView further author information
,
Jing LiuBurning Rock Biotech, Guangzhou, Guangdong Province, ChinaView further author information
&
Qiang ZuoDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, ChinaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-2492-3489View further author information
ORCID Icon show all
Pages 359-363 | Received 28 Aug 2017, Accepted 23 Jan 2018, Published online: 06 Mar 2018

References

  • Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53. doi:10.1200/JCO.2009.22.6993. PMID:19667264.
  • Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–33. doi:10.1158/2159-8290.CD-16-0596. PMID:27432227.
  • Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng Y-L, Liu W, Dardaei L, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374:54–61. doi:10.1056/NEJMoa1508887. PMID:26698910.
  • Jiang T, Ren S, Zhou C. Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer. 2015;90:128–34. doi:10.1016/j.lungcan.2015.09.013. PMID:26415994.
  • Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479–91. doi:10.1158/2159-8290.CD-15-1483. PMID:26969689.
  • Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28:70–81. doi:10.1016/j.ccell.2015.05.010. PMID:26144315.
  • Ou S-HI, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang Y-J, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6:942–6. doi:10.1097/JTO.0b013e31821528d3. PMID:21623265.
  • Paik PK, Drilon A, Fan P-D, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5:842–9. doi:10.1158/2159-8290.CD-14-1467. PMID:25971939.
  • Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77. doi:10.1056/NEJMoa1408440. PMID:25470694.
  • Shaw AT, Kim TM, Crino L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:874–86. doi:10.1016/S1470-2045(17)30339-X. PMID:28602779.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.